Exelixis, Inc. (NASDAQ:EXEL – Free Report) – Stock analysts at Leerink Partnrs cut their Q4 2024 earnings estimates for shares of Exelixis in a report released on Monday, October 28th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings of $0.35 per share for the quarter, down from their previous forecast of $0.36. The consensus estimate for Exelixis’ current full-year earnings is $1.58 per share.
Exelixis (NASDAQ:EXEL – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.44. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. The firm had revenue of $637.18 million for the quarter, compared to the consensus estimate of $468.21 million.
Read Our Latest Research Report on EXEL
Exelixis Stock Performance
NASDAQ EXEL opened at $28.73 on Tuesday. The stock has a market cap of $8.20 billion, a PE ratio of 24.77, a P/E/G ratio of 0.61 and a beta of 0.54. The firm has a 50-day moving average of $26.69 and a 200-day moving average of $24.09. Exelixis has a 52-week low of $19.20 and a 52-week high of $29.75.
Insiders Place Their Bets
In other news, EVP Jeffrey Hessekiel sold 25,000 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $26.38, for a total value of $659,500.00. Following the completion of the transaction, the executive vice president now directly owns 605,325 shares in the company, valued at approximately $15,968,473.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total value of $3,398,750.00. Following the completion of the transaction, the chief financial officer now directly owns 721,680 shares in the company, valued at approximately $19,622,479.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $26.38, for a total transaction of $659,500.00. Following the transaction, the executive vice president now directly owns 605,325 shares of the company’s stock, valued at $15,968,473.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 327,858 shares of company stock valued at $8,640,129. 2.85% of the stock is currently owned by insiders.
Institutional Trading of Exelixis
A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXEL. LSV Asset Management boosted its stake in shares of Exelixis by 107.7% in the 2nd quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock valued at $129,511,000 after purchasing an additional 2,989,021 shares during the last quarter. Jupiter Asset Management Ltd. boosted its position in Exelixis by 148.2% during the first quarter. Jupiter Asset Management Ltd. now owns 2,267,894 shares of the biotechnology company’s stock valued at $53,817,000 after acquiring an additional 1,354,062 shares during the last quarter. Swedbank AB acquired a new stake in Exelixis during the 1st quarter worth about $22,455,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Exelixis in the 1st quarter worth about $10,906,000. Finally, Farallon Capital Management LLC lifted its stake in shares of Exelixis by 1.6% in the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after purchasing an additional 424,000 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Recommended Stories
- Five stocks we like better than Exelixis
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- Dividend Capture Strategy: What You Need to Know
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- What is a Special Dividend?
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.